Valuation: Virbac SA

Market Cap 2.58B 2.91B 2.41B 2.2B 4.14B 279B 4.18B 29.16B 11.3B 143B 10.91B 10.67B 458B P/E 2026 *
14.9x
P/E 2027 * 13.4x
Enterprise Value 2.7B 3.04B 2.52B 2.3B 4.34B 293B 4.38B 30.54B 11.83B 150B 11.43B 11.18B 480B EV / Sales 2026 *
1.75x
EV / Sales 2027 * 1.6x
Free-Float
49.03%
Yield 2026 *
0.56%
Yield 2027 * 0.66%
Manager TitleAgeSince
Chief Executive Officer 46 01/09/2025
Chief Executive Officer 50 27/09/2024
Chief Operating Officer 64 01/01/2022
Director TitleAgeSince
Chairman 61 01/04/2006
Director/Board Member 68 28/07/2010
Director/Board Member 65 05/09/2017
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.91B
-0.61%-3.43%+36.07%+117.61% 1,019B
-1.02%-5.60%+35.72%+64.82% 617B
+1.11%-0.58%+12.36%+78.27% 464B
+0.34%-3.01%+61.79%+41.79% 356B
-0.95%-4.05%+20.54%+40.33% 333B
-1.46%-2.89%+10.57%+26.54% 267B
-1.35%-5.43%-6.17%+8.82% 244B
-1.04%-2.79%+35.30%+54.42% 218B
-1.87%-4.10%+28.44%+97.54% 179B
Average -0.76%-3.39%+26.07%+58.90% 410.8B
Weighted average by Cap. -0.60%-3.33%+29.07%+71.15%

Financials

2026 *2027 *
Net sales 1.55B 1.74B 1.44B 1.32B 2.48B 167B 2.51B 17.48B 6.77B 85.58B 6.54B 6.4B 275B 1.64B 1.85B 1.53B 1.4B 2.64B 178B 2.66B 18.57B 7.2B 90.95B 6.95B 6.8B 292B
Net income 174M 196M 162M 148M 279M 18.82B 282M 1.96B 761M 9.62B 735M 719M 30.87B 194M 218M 181M 165M 311M 20.96B 314M 2.19B 848M 10.72B 819M 801M 34.39B
Net Debt 122M 138M 114M 104M 196M 13.24B 198M 1.38B 536M 6.77B 517M 506M 21.73B 44.72M 50.33M 41.74M 38.04M 71.75M 4.84B 72.42M 505M 196M 2.47B 189M 185M 7.94B
Logo Virbac SA
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
308.00EUR
Average target price
412.75EUR
Spread / Average Target
+34.01%

Quarterly revenue - Rate of surprise